Medication for dogs is causing illness and death.

It has recently come to light that a medication called Librela, used to alleviate pain in dogs with osteoarthritis, may actually be causing harm to our furry friends. The US Food and Drug Administration approved this medication, also known as bedinvetmab injection, in May of 2023. However, after receiving numerous reports from concerned pet owners, the FDA has issued a letter to veterinarians warning them of potential adverse effects.

According to the FDA's evaluation, dogs who have been given Librela have experienced a range of negative symptoms, including seizures, ataxia, and even death. In some cases, these side effects have been so severe that they have resulted in the loss of the dog's life. From 2023 to March of this year, there have been over 3,600 reported cases of adverse reactions to Librela.

This medication is administered through a subcutaneous injection once a month, with the dosage determined by the dog's weight. If a veterinarian notices any concerning symptoms in a dog who has been given Librela, they are urged to report it to the drug sponsor, Zoetis, who is then required to inform the FDA. Alternatively, vets can also report these incidents directly to the FDA.

It is worth noting that the FDA had initially reviewed studies on Librela and deemed it safe for use in controlling pain from osteoarthritis before granting approval. Zoetis, the drug's manufacturer, has also stated that Librela has been used successfully on millions of dogs in Europe since its launch three years ago. They stand by the safety and effectiveness of their product, despite the recent reports.

In fact, Zoetis had high hopes for Librela, with CEO Kristin Peck projecting it to become a billion-dollar franchise. However, the FDA's letter has raised concerns about the medication's safety and potential harm to dogs. This news comes on the heels of another concerning issue in the pet industry, as a dog food manufacturer recently recalled 400 bags of treats due to possible Salmonella contamination.

In conclusion, while Librela may have been thought to be a safe option for managing pain in dogs with osteoarthritis, the recent reports and FDA's letter have raised doubts about its safety. Pet owners and veterinarians alike should be aware of the potential adverse effects and take necessary precautions. As always, the health and well-being of our furry companions should be our top priority.

[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]